When working-age adults develop cardiovascular disease, it often ends up eating up a significant amount of their income. Are insurance companies doing enough to help these patients?
The American Association for Thoracic Surgery has announced a new partnership with the Cardiothoracic Surgical Trials Network. The groups plan on working together to address current challenges in cardiothoracic surgery research.
Oversizing transcatheter heart valves can improve TAVR outcomes. There is still a reason to be cautious, however, especially when patients are receiving a balloon-expandable valve.
More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
